Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Payables (2017 - 2025)

Sutro Biopharma's Payables history spans 9 years, with the latest figure at $7.0 million for Q3 2025.

  • For Q3 2025, Payables rose 13.16% year-over-year to $7.0 million; the TTM value through Sep 2025 reached $7.0 million, up 13.16%, while the annual FY2024 figure was $10.5 million, 10.96% up from the prior year.
  • Payables for Q3 2025 was $7.0 million at Sutro Biopharma, up from $4.3 million in the prior quarter.
  • Across five years, Payables topped out at $12.6 million in Q2 2022 and bottomed at $3.9 million in Q2 2023.
  • The 5-year median for Payables is $7.0 million (2025), against an average of $7.6 million.
  • The largest annual shift saw Payables surged 129.0% in 2021 before it plummeted 69.32% in 2023.
  • A 5-year view of Payables shows it stood at $6.0 million in 2021, then decreased by 20.17% to $4.8 million in 2022, then surged by 96.79% to $9.4 million in 2023, then rose by 10.96% to $10.5 million in 2024, then tumbled by 32.85% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Payables are $7.0 million (Q3 2025), $4.3 million (Q2 2025), and $8.2 million (Q1 2025).